Show simple item record

dc.contributor.authorWu, Wendy Yi-Ying
dc.contributor.authorHaider, Zahra
dc.contributor.authorFeng, Xiaoshuang
dc.contributor.authorHeath, Alicia K.
dc.contributor.authorTjønneland, Anne
dc.contributor.authorAgudo, Antonio
dc.contributor.authorMasala, Giovanna
dc.contributor.authorRobbins, Hilary A.
dc.contributor.authorHuerta, María-José
dc.contributor.authorGuevara, Marcela
dc.contributor.authorSchulze, Matthias B.
dc.contributor.authorRodriguez-Barranco, Miguel
dc.contributor.authorVineis, Paolo
dc.contributor.authorTumino, Rosario
dc.contributor.authorKaaks, Rudolf
dc.contributor.authorFortner, Renée T.
dc.contributor.authorSieri, Sabina
dc.contributor.authorPanico, Salvatore
dc.contributor.authorNøst, Therese Haugdahl
dc.contributor.authorSandanger, Torkjel M
dc.contributor.authorBraaten, Tonje
dc.contributor.authorJohansson, Mattias
dc.contributor.authorMelin, Beatrice
dc.contributor.authorJohansson, Mikael
dc.date.accessioned2023-01-13T09:39:20Z
dc.date.available2023-01-13T09:39:20Z
dc.date.issued2022-10-28
dc.description.abstractThe EarlyCDT-Lung test is a blood-based autoantibody assay intended to identify high-risk individuals for low-dose computed tomography lung cancer screening. However, there is a paucity of evidence on the performance of the EarlyCDT-Lung test in ever-smokers. We conducted a nested case-control study within two prospective cohorts to evaluate the risk-discriminatory performance of the EarlyCDT-Lung test using prediagnostic blood samples from 154 future lung cancer cases and 154 matched controls. Cases were selected from those who had ever smoked and had a prediagnostic blood sample <3 years prior to diagnosis. Conditional logistic regression was used to estimate the association between EarlyCDT-Lung test results and lung cancer risk. Sensitivity and specificity of the EarlyCDT-Lung test were calculated in all subjects and subgroups based on age, smoking history, lung cancer stage, sample collection time before diagnosis and year of sample collection. The overall lung cancer odds ratios were 0.89 (95% CI: 0.34-2.30) for a moderate risk EarlyCDT-Lung test result and 1.09 (95% CI: 0.48-2.47) for a high-risk test result compared to no significant test result. The overall sensitivity was 8.4% (95% CI: 4.6-14) and overall specificity was 92% (95% CI: 87-96) when considering a high-risk result as positive. Stratified analysis indicated higher sensitivity (17%, 95% CI: 7.2-32.1) in subjects with blood drawn up to 1 year prior to diagnosis. In conclusion, our study does not support a role of the EarlyCDT-Lung test in identifying the high-risk subjects in ever-smokers for lung cancer screening in the EPIC and NSHDS cohorts.en_US
dc.identifier.citationWu, Haider, Feng, Heath, Tjønneland, Agudo, Masala, Robbins, Huerta, Guevara, Schulze, Rodriguez-Barranco, Vineis, Tumino, Kaaks, Fortner, Sieri, Panico, Nøst, Sandanger, Braaten, Johansson, Melin, Johansson. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts. International Journal of Cancer. 2022en_US
dc.identifier.cristinIDFRIDAID 2087106
dc.identifier.doi10.1002/ijc.34340
dc.identifier.issn0020-7136
dc.identifier.issn1097-0215
dc.identifier.urihttps://hdl.handle.net/10037/28191
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalInternational Journal of Cancer
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleAssessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohortsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)